Sector News

Novo Nordisk joins pharma’s IPO clique with plans for tech subsidiary spinoff

February 10, 2015
Life sciences
It’s official: Novo Nordisk has joined the spinoff club. The Danish drugmaker says it’s ready to let its information technology unit, NNIT, go solo via an initial public offering.
 
Few details are available at the moment; Novo Nordisk announced the decision in a bare-bones press release. The company says it will take place in 4-5 weeks, but won’t say how big the offering might be. What’s certain is that it’s another example of a drugmaker sharpening its focus by hiving off subsidiaries and business units.
 
Novo has been weighing the prospect since last January, when the company named a new CFO for NNIT, Carsten Krogsgaard Thomsen, and charged him with reviewing a spinoff. In March, Novo hired Morgan Stanley and Danske Bank to advise on the potential offering. The questions were the usual ones: Could hiving off NNIT “create value”? Would NNIT be better off on its own?
 
Independence might make it easier for NNIT to compete for clients. NNIT brought in about 2.2 billion kroner in 2013, or about $404 million, and external customers have accounted for an increasing share of those sales. For 2014, that share was expected to be about 50%. That’s one reason why Novo was looking at a stock offering, Thomsen said last year.
 
“An IPO will provide the company with improved access to the capital markets and stronger brand recognition, among other benefits,” NNIT said in a separate press release (as quoted by Reuters).
 
The IT unit has been edging its way toward solo status for years. Novo Nordisk formally set NNIT aside in an independent, wholly owned subsidiary back in 1998. Last year’s sales amounted to 2.4 billion kroner.
 
Novo’s is the second spinoff announcement so far this year. Last week, GlaxoSmithKline said it was moving toward an IPO for its HIV joint venture, ViiV Healthcare, and would decide for certain by midyear. That would be a much bigger deal; with its £1.5 billion in 2014 sales, analysts see ViiV valued at £12 billion to £18 billion ($18 billion to $27 billion). 
 
By Tracy Staton
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.